Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca Concentrates Biologics At MedImmune, Ups R&D

This article was originally published in The Pink Sheet Daily

Executive Summary

MedImmune, which absorbs Cambridge Antibody Technologies, will continue to operate independently from AstraZeneca.

You may also be interested in...



Tie-Up With MedImmune Marks Catalyst's Second Partnership Deal In A Week

The collaboration involves discovery work on undisclosed targets in the autoimmune and inflammatory disease areas.

Tie-Up With MedImmune Marks Catalyst's Second Partnership Deal In A Week

The collaboration involves discovery work on undisclosed targets in the autoimmune and inflammatory disease areas.

MedImmune Appoints Development Leadership Team

Former Cambridge Antibody Technology exec to oversee product development.

Related Content

Topics

UsernamePublicRestriction

Register

PS065601

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel